Download
s00103-020-03227-3.pdf 1,34MB
WeightNameValue
1000 Titel
  • Individualisierte Immuntherapie von Tumorerkrankungen mittels Peptidimpfstoffen – Funktioniert das vielleicht doch?
1000 Titelzusatz
  • Individualized immunotherapy for malignant tumors using peptide vaccines—maybe it does work after all?
1000 Autor/in
  1. Rammensee, Hans-Georg |
  2. Löffler, Markus W. |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-10-09
1000 Erschienen in
1000 Quellenangabe
  • 63(11):1380-1387
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00103-020-03227-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648007/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • The physician and scientist Paul Ehrlich put forward the thesis that the immune system not only fights infections but can also fight cancer. The possible positive effects of a simultaneous infection on the course of cancer were reported in ancient Egypt around 2600 BC. However, it was not until the 1960s that it became apparent that the immune system could specifically fight cancer cells, and it was not until the 1990s that researchers slowly clarified how this happens.Against this background, the efforts over the last 30 years to develop therapeutic vaccines against cancers are briefly summarized, and their lack of success to date is highlighted. In addition, potentially promising future developments in this context are discussed. The available scientific literature as well as our own results are taken into account.Central questions arise, such as the following: How do cancer cells differ from normal cells? How can the immune system recognize these differences? What are tumor-specific antigens? Why do they need to be selected and applied in an individualized fashion? How can an efficient immune response be induced? Which pharmaceutical formulations, adjuvants, and vaccination routes are effective?Finally, we explain why it may still be worth pursuing peptide vaccination, which has so far been completely unsuccessful (when measured in terms of already approved therapeutics).
1000 Sacherschließung
lokal Therapeutic vaccination
lokal Neoplasms/prevention
lokal Leitthema
lokal Humans [MeSH]
lokal Immunotherapy [MeSH]
lokal Cancer antigens
lokal Krebsantigene
lokal Peptide
lokal HLA-Moleküle
lokal Peptides
lokal T lymphocytes
lokal Cancer Vaccines/therapeutic use [MeSH]
lokal Antigens, Neoplasm [MeSH]
lokal Therapeutische Vakzinierung
lokal Germany [MeSH]
lokal T‐Lymphozyten
lokal HLA molecules
lokal Vaccines, Subunit/therapeutic use [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UmFtbWVuc2VlLCBIYW5zLUdlb3Jn|https://frl.publisso.de/adhoc/uri/TMO2ZmZsZXIsIE1hcmt1cyBXLg==
1000 Hinweis
  • DeepGreen-ID: 63d139de7d0043e38443d678ddf342ec ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6441679.rdf
1000 Erstellt am 2023-04-25T18:05:03.235+0200
1000 Erstellt von 322
1000 beschreibt frl:6441679
1000 Zuletzt bearbeitet 2023-10-19T10:45:09.372+0200
1000 Objekt bearb. Thu Oct 19 10:45:09 CEST 2023
1000 Vgl. frl:6441679
1000 Oai Id
  1. oai:frl.publisso.de:frl:6441679 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source